Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): clinical experience of the Galician Lung Cancer Group

•Real-world study of first-line afatinib in patients with Del19 EGFR NSCLC.•Treatment-naïve patients with Del19 EGFR NSCLC reported long PFS with afatinib.•Older patients (> 70 years) benefitted from afatinib as much as younger patients.•Safety profile of afatinib as expected, with more dose reductions in older patients.•Afatinib may be an option for patients with Del19 EGFR NSCLC, even in those who are older.